{"nct_id":"NCT02951156","title":"Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","status":"TERMINATED","status_verified_date":"2020-11","start_date":"2016-12-16","start_date_type":"ACTUAL","primary_completion_date":"2019-12-02","primary_completion_date_type":"ACTUAL","completion_date":"2019-12-02","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["PFE"]}